In EDS ansehen

Asprosin Levels in Adults with Type 2 Diabetes Mellitus and Diabetic Kidney Disease: A Systematic Review and Meta-Analysis

Gespeichert in:
Bibliographische Detailangaben
Titel: Asprosin Levels in Adults with Type 2 Diabetes Mellitus and Diabetic Kidney Disease: A Systematic Review and Meta-Analysis
Autoren: Jovana Ristic, Sena Kodalak, Gonzalo Peralta-Jiménez, Maria Moura de Lima, Marijana Kovacevic, Srdjan Masic, Tatjana Nikolic
Quelle: Diabetes Metab Syndr Obes
Diabetes, Metabolic Syndrome and Obesity, Vol Volume 18, Iss Issue 1, Pp 2493-2506 (2025)
Verlagsinformationen: Informa UK Limited, 2025.
Publikationsjahr: 2025
Schlagwörter: adipokine, RC581-951, diabetes mellitus, eGFR, Specialties of internal medicine, Review, diabetic kidney disease, asprosin
Beschreibung: PURPOSE: Diabetic kidney disease (DKD) significantly affects health and healthcare costs due to chronic kidney disease complications. Given asprosin’s potential as a biomarker for disease progression, we conducted the first systematic review and meta-analysis on its relationship with DKD in adults with type 2 diabetes mellitus (T2DM). METHODS: PubMed, Embase, Cochrane, and Web of Science were systematically searched. Standard mean differences (SMD) with 95% confidence intervals (CI) and Fisher’s Z transformation were used to examine the relationship between asprosin and DKD. The risk of bias was evaluated using the Newcastle-Ottawa Scale (NOS) and its version for cross-sectional studies. Heterogeneity (I² > 50%) was analyzed with a random-effects model. RESULTS: Six studies (n = 1340) were included. Meta-analysis results indicated that T2DM patients with DKD (micro/macroalbuminuria) had significantly higher circulating asprosin levels than normoalbuminuric T2DM patients (SMD: 1.5, 95% CI: 0.69–2.32, p = 0.0003). Meta-analysis of correlation revealed a positive association of asprosin with urinary albumin excretion ratio (UACR) (Fisher’s Z = 0.4; 95% CI: 0.240–0.554, p < 0.001) and body mass index (BMI) (Fisher’s Z = 0.17; 95% CI: 0.036–0.301, p = 0.013), and a negative association with estimated glomerular filtration rate (eGFR) (Fisher’s Z = −0.35; 95% CI: −0.471 to −0.239, p < 0.001). CONCLUSION: Asprosin is elevated in T2DM patients with pre-DKD (early stage DKD) and DKD and correlates with key markers of disease severity. Additional research is required to better understand the pathophysiological mechanisms of asprosin and its role in DKD.
Publikationsart: Article
Other literature type
Sprache: English
ISSN: 1178-7007
DOI: 10.2147/dmso.s527579
Zugangs-URL: https://doaj.org/article/0bb336a9183d42a3a870f94533b90eaa
Rights: CC BY NC
URL: http://creativecommons.org/licenses/by-nc/4.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at http://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v4.0) License (http://creativecommons.org/licenses/by-nc/4.0/ (http://creativecommons.org/licenses/by-nc/4.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (http://www.dovepress.com/terms.php).
Dokumentencode: edsair.doi.dedup.....b70b0e11fc856f34252e7663f9cef36b
Datenbank: OpenAIRE
Beschreibung
Abstract:PURPOSE: Diabetic kidney disease (DKD) significantly affects health and healthcare costs due to chronic kidney disease complications. Given asprosin’s potential as a biomarker for disease progression, we conducted the first systematic review and meta-analysis on its relationship with DKD in adults with type 2 diabetes mellitus (T2DM). METHODS: PubMed, Embase, Cochrane, and Web of Science were systematically searched. Standard mean differences (SMD) with 95% confidence intervals (CI) and Fisher’s Z transformation were used to examine the relationship between asprosin and DKD. The risk of bias was evaluated using the Newcastle-Ottawa Scale (NOS) and its version for cross-sectional studies. Heterogeneity (I² > 50%) was analyzed with a random-effects model. RESULTS: Six studies (n = 1340) were included. Meta-analysis results indicated that T2DM patients with DKD (micro/macroalbuminuria) had significantly higher circulating asprosin levels than normoalbuminuric T2DM patients (SMD: 1.5, 95% CI: 0.69–2.32, p = 0.0003). Meta-analysis of correlation revealed a positive association of asprosin with urinary albumin excretion ratio (UACR) (Fisher’s Z = 0.4; 95% CI: 0.240–0.554, p < 0.001) and body mass index (BMI) (Fisher’s Z = 0.17; 95% CI: 0.036–0.301, p = 0.013), and a negative association with estimated glomerular filtration rate (eGFR) (Fisher’s Z = −0.35; 95% CI: −0.471 to −0.239, p < 0.001). CONCLUSION: Asprosin is elevated in T2DM patients with pre-DKD (early stage DKD) and DKD and correlates with key markers of disease severity. Additional research is required to better understand the pathophysiological mechanisms of asprosin and its role in DKD.
ISSN:11787007
DOI:10.2147/dmso.s527579